MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Arbutus Biopharma Corp

Cerrado

3.17 2.92

Resumen

Variación precio

24h

Actual

Mínimo

3.03

Máximo

3.22

Métricas clave

By Trading Economics

Ingresos

-12M

-25M

Ventas

190K

1.8M

BPA

-0.182

Margen de beneficio

-1,390.363

Empleados

44

EBITDA

-12M

-24M

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

12M

653M

Apertura anterior

0.25

Cierre anterior

3.17

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Arbutus Biopharma Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 jul 2025, 23:09 UTC

Ganancias

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 jul 2025, 19:16 UTC

Adquisiciones, fusiones, absorciones

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 jul 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 jul 2025, 23:41 UTC

Charlas de Mercado

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 jul 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 jul 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 jul 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

James Hardie Completes Acquisition of AZEK

1 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 jul 2025, 20:24 UTC

Ganancias

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 jul 2025, 19:55 UTC

Charlas de Mercado

Oil Futures Resume Cautious Rally -- Market Talk

1 jul 2025, 19:27 UTC

Charlas de Mercado

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 jul 2025, 19:12 UTC

Charlas de Mercado

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 jul 2025, 19:01 UTC

Adquisiciones, fusiones, absorciones

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 jul 2025, 18:41 UTC

Adquisiciones, fusiones, absorciones

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 jul 2025, 18:33 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

1 jul 2025, 18:33 UTC

Charlas de Mercado

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 jul 2025, 18:32 UTC

Charlas de Mercado

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 jul 2025, 18:22 UTC

Charlas de Mercado

Remittances to Mexico Down in May -- Market Talk

1 jul 2025, 17:45 UTC

Charlas de Mercado

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 jul 2025, 17:01 UTC

Adquisiciones, fusiones, absorciones

Danone Completed Acquisition of Majority Stake in Kate Farms

1 jul 2025, 16:55 UTC

Ganancias

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 jul 2025, 16:27 UTC

Charlas de Mercado

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 jul 2025, 16:25 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jul 2025, 15:48 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 jul 2025, 15:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 jul 2025, 15:46 UTC

Charlas de Mercado

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 jul 2025, 14:54 UTC

Charlas de Mercado

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 jul 2025, 14:49 UTC

Charlas de Mercado

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparación entre iguales

Cambio de precio

Arbutus Biopharma Corp Esperado

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.255 / 3.365Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.